Skip to content
Important: This site presents data from the FDA Adverse Event Reporting System (FAERS). A report does not mean the drug caused the event. Full disclaimer.

Does AMIVANTAMAB-VMJW Cause Interstitial lung disease? 16 Reports in FDA Database

Boost Your Natural Energy & Metabolism

Mitolyn — 6 exotic plants to unlock your body's fat-burning power. 90-day guarantee.

Try Mitolyn Now

According to the FDA Adverse Event Reporting System (FAERS), 16 reports of Interstitial lung disease have been filed in association with AMIVANTAMAB-VMJW. This represents 0.8% of all adverse event reports for AMIVANTAMAB-VMJW.

16
Reports of Interstitial lung disease with AMIVANTAMAB-VMJW
0.8%
of all AMIVANTAMAB-VMJW reports
4
Deaths
0
Hospitalizations

How Dangerous Is Interstitial lung disease From AMIVANTAMAB-VMJW?

Of the 16 reports, 4 (25.0%) resulted in death, and 4 (25.0%) were considered life-threatening.

Is Interstitial lung disease Listed in the Official Label?

This adverse event is not currently listed in the official FDA drug label for AMIVANTAMAB-VMJW. However, 16 reports have been filed with the FAERS database.

What Other Side Effects Does AMIVANTAMAB-VMJW Cause?

Infusion related reaction (509) Rash (315) Off label use (130) Dyspnoea (81) Paronychia (78) Nausea (65) Oxygen saturation decreased (55) Flushing (54) Death (53) Non-small cell lung cancer (51)

What Other Drugs Cause Interstitial lung disease?

METHOTREXATE (3,049) RITUXIMAB (2,458) PEMBROLIZUMAB (2,113) PREDNISONE (1,850) CYCLOPHOSPHAMIDE (1,725) NIVOLUMAB (1,538) AMIODARONE (1,421) DOXORUBICIN (1,352) ETANERCEPT (1,267) ADALIMUMAB (1,250)

Which AMIVANTAMAB-VMJW Alternatives Have Lower Interstitial lung disease Risk?

AMIVANTAMAB-VMJW vs AMLODIPINE AMIVANTAMAB-VMJW vs AMLODIPINE BESILATE AMIVANTAMAB-VMJW vs AMLODIPINE\ATORVASTATIN AMIVANTAMAB-VMJW vs AMLODIPINE\BENAZEPRIL AMIVANTAMAB-VMJW vs AMLODIPINE\HYDROCHLOROTHIAZIDE\OLMESARTAN

Related Pages

AMIVANTAMAB-VMJW Full Profile All Interstitial lung disease Reports All Drugs Causing Interstitial lung disease AMIVANTAMAB-VMJW Demographics